Clinical effectiveness of hemoglobin spray (Granulox®) as adjunctive therapy in the treatment of chronic diabetic foot ulcers.

Q1 Health Professions Diabetic Foot & Ankle Pub Date : 2016-11-07 eCollection Date: 2016-01-01 DOI:10.3402/dfa.v7.33101
Sharon D Hunt, Fredrik Elg
{"title":"Clinical effectiveness of hemoglobin spray (Granulox<sup>®</sup>) as adjunctive therapy in the treatment of chronic diabetic foot ulcers.","authors":"Sharon D Hunt, Fredrik Elg","doi":"10.3402/dfa.v7.33101","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Hemoglobin spray (Granulox<sup>®</sup>) comprises purified hemoglobin and is a novel approach for increasing oxygen availability in the wound bed in diabetic foot ulcer patients. Its mode of action is to bind oxygen from the atmosphere and diffuse it into the wound bed to accelerate wound healing in slow-healing wounds.</p><p><strong>Patients and methods: </strong>Wound healing outcomes, that is, wound size, pain, percentage of slough, and exudate levels, were compared retrospectively to a similar cohort of patients treated over the same period the previous year. The same inclusion and exclusion criteria applied to both groups.</p><p><strong>Results: </strong>All 20 (100%) hemoglobin spray-treated patients and 15 (75%) control patients experienced some wound healing by week 4, with 5 (25%) and 1 (5%), respectively, achieving complete wound closure. At week 4, mean wound size reduction was 63% in the hemoglobin spray group versus 26% for controls, increasing to 95% reduction at week 28 in the hemoglobin spray group versus 63% for controls (<i>p<</i>0.05 at all timepoints). Hemoglobin spray was associated with substantially lower pain scores using a 10-cm visual analogue scale, with 19/19 patients (100%) being pain-free from week 12 onwards, compared to 6/18 patients (33%) in the control group. At week 28, 2/18 patients (11%) in the control group still had pain. Both groups had similar baseline slough levels, but hemoglobin spray-treated wounds had slough completely eliminated after 4 weeks versus 10% mean reduction in the control group (<i>p<</i>0.001). Hemoglobin spray was associated with markedly reduced exudate levels; within 4 weeks, no patients had high exudate levels in the hemoglobin spray group versus 5 in the control group.</p><p><strong>Conclusion: </strong>Standard wound care plus hemoglobin spray results in improvements in wound closure, wound size reduction, pain, slough, and exudate levels compared to control patients for chronic diabetic foot ulcer treatment.</p>","PeriodicalId":45385,"journal":{"name":"Diabetic Foot & Ankle","volume":"7 1","pages":"33101"},"PeriodicalIF":0.0000,"publicationDate":"2016-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5102129/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetic Foot & Ankle","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3402/dfa.v7.33101","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2016/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Health Professions","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Hemoglobin spray (Granulox®) comprises purified hemoglobin and is a novel approach for increasing oxygen availability in the wound bed in diabetic foot ulcer patients. Its mode of action is to bind oxygen from the atmosphere and diffuse it into the wound bed to accelerate wound healing in slow-healing wounds.

Patients and methods: Wound healing outcomes, that is, wound size, pain, percentage of slough, and exudate levels, were compared retrospectively to a similar cohort of patients treated over the same period the previous year. The same inclusion and exclusion criteria applied to both groups.

Results: All 20 (100%) hemoglobin spray-treated patients and 15 (75%) control patients experienced some wound healing by week 4, with 5 (25%) and 1 (5%), respectively, achieving complete wound closure. At week 4, mean wound size reduction was 63% in the hemoglobin spray group versus 26% for controls, increasing to 95% reduction at week 28 in the hemoglobin spray group versus 63% for controls (p<0.05 at all timepoints). Hemoglobin spray was associated with substantially lower pain scores using a 10-cm visual analogue scale, with 19/19 patients (100%) being pain-free from week 12 onwards, compared to 6/18 patients (33%) in the control group. At week 28, 2/18 patients (11%) in the control group still had pain. Both groups had similar baseline slough levels, but hemoglobin spray-treated wounds had slough completely eliminated after 4 weeks versus 10% mean reduction in the control group (p<0.001). Hemoglobin spray was associated with markedly reduced exudate levels; within 4 weeks, no patients had high exudate levels in the hemoglobin spray group versus 5 in the control group.

Conclusion: Standard wound care plus hemoglobin spray results in improvements in wound closure, wound size reduction, pain, slough, and exudate levels compared to control patients for chronic diabetic foot ulcer treatment.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
血红蛋白喷雾剂(Granulox®)作为辅助疗法治疗慢性糖尿病足溃疡的临床效果。
简介血红蛋白喷雾剂(Granulox®)由纯化血红蛋白组成,是增加糖尿病足溃疡患者伤口床氧气供应的一种新方法。其作用模式是结合大气中的氧气并将其扩散到伤口床,以加速愈合缓慢伤口的愈合:将伤口愈合结果,即伤口大小、疼痛、蜕皮百分比和渗液水平,与前一年同期接受治疗的类似患者进行回顾性比较。两组患者的纳入和排除标准相同:所有 20 名(100%)接受过血红蛋白喷雾治疗的患者和 15 名(75%)接受过血红蛋白喷雾治疗的对照组患者的伤口在第 4 周时都有所愈合,其中分别有 5 名(25%)和 1 名(5%)患者的伤口完全闭合。第 4 周时,血红蛋白喷剂组的平均伤口面积缩小了 63%,而对照组缩小了 26%;第 28 周时,血红蛋白喷剂组的平均伤口面积缩小了 95%,而对照组缩小了 63%(在所有时间点上,P 均为 0.05)。使用 10 厘米视觉模拟量表进行疼痛评分时,血红蛋白喷雾剂可显著降低疼痛评分,从第 12 周起,19/19 例患者(100%)无痛,而对照组为 6/18 例(33%)。第 28 周时,对照组有 2/18 名患者(11%)仍有疼痛感。两组患者的基线蜕皮水平相似,但经过血红蛋白喷雾治疗的伤口在 4 周后蜕皮完全消除,而对照组平均减少 10%(P0.001)。血红蛋白喷雾剂可显著降低渗液水平;4 周内,血红蛋白喷雾剂组没有患者出现渗液水平过高的情况,而对照组有 5 例:结论:在慢性糖尿病足溃疡治疗中,标准伤口护理加血红蛋白喷剂可改善伤口闭合、伤口缩小、疼痛、糜烂和渗液水平。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Diabetic Foot & Ankle
Diabetic Foot & Ankle ENDOCRINOLOGY & METABOLISM-
CiteScore
4.80
自引率
0.00%
发文量
0
期刊最新文献
Limb salvage in diabetic patients with no-option critical limb ischemia: outcomes of a specialized center experience. Serum vitamin D and diabetic foot complications. Diabetes-related foot disorders among adult Ghanaians. Cost-effectiveness analysis of the human recombinant epidermal growth factor in the management of patients with diabetic foot ulcers. Diabetic foot ulcer outcomes from a podiatry led tertiary service in Kuwait.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1